Non-radiographic axial spondyloarthritis (nr-axSpA) is a chronic inflammatory disease belonging to the group of spondyloarthritides. This disorder is characterized by widespread joint inflammation, primarily in the spine and sacroiliac joints, without detectable radiographic changes in the initial stages. The main pathogenetic mechanism for the development of nr-axSpA is a disorder of the immune system, which leads to chronic joint inflammation. This form of axial spondyloarthritis can significantly affect the quality of life of patients, leading to pain syndromes, limited mobility and decreased functional capabilities. In addition, this disease is often associated with other systemic inflammatory diseases, such as inflammatory bowel disease and psoriasis, which makes it relevant for comprehensive study in medicine.
History of the disease and interesting historical facts
The history of the study of spondyloarthritis dates back to the late 19th century, when ankylosing spondylitis was initially described. However, non-radiographic axial spondyloarthritis was not recognized as a distinct pathology until the late 20th century. In 2009, the World Health Organization included nr-axSpA in its classification of diseases, reflecting the growing understanding of this pathology. Interestingly, the first descriptions of features compatible with nr-axSpA occurred in the works of physicians describing cases of patients with non-specific back pain, which were later associated with inflammatory processes affecting the joints. In turn, historical studies also indicate a high incidence rate among certain ethnic groups, such as Celts and Scandinavians, which has maintained interest in this disease in the context of ethnic predisposition.
Epidemiology
The epidemiology of non-radiographic axial spondyloarthritis shows a significant prevalence of this disease in various populations. According to current data, nr-axSpA occurs in 0.1-0.2% of the general population, but among individuals with spondylitis-like symptoms, this number can reach 5-10%. The disease is most often diagnosed in young people, mainly in men aged 20 to 40 years, but in recent years there has been an increased interest in female forms of this condition. Some studies suggest that women may demonstrate slightly different clinical manifestations of the disease, including less pronounced postural changes and a greater predisposition to migratory pain syndromes. Thus, nr-axSpA has certain epidemiological features that require further research to identify the various factors influencing the incidence and course of the disease in different population groups.
Genetic predisposition to this disease
Genetic predisposition plays a significant role in the development of non-radiographic axial spondyloarthritis. Studies have shown that the HLA-B27 gene, associated with an increased risk of developing spondyloarthritis, is present in more than 80% patients with nr-axSpA. However, the presence of this gene is not a prerequisite for the development of the disease, since most HLA-B27 carriers do not suffer from nr-axSpA. Additionally, in recent years, other genetic markers have been identified that may be associated with this disease, including genes responsible for the immune response, such as IL23R and ERAP1. Some studies even establish a link with polymorphisms in genes involved in inflammatory processes, indicating a complex and multifaceted mechanism that contributes to the occurrence and progression of nr-axSpA.
Risk factors for the development of this disease
Risk factors predisposing to the development of non-radiographic axial spondyloarthritis are varied and may include both genetic and environmental aspects. Structurally, risk factors can be classified as follows:
- Physical factors: professional activities associated with physical stress; regular sports activities; spinal injuries.
- Chemical factors: exposure to certain toxic substances, possibly including lead and other metals, which can trigger autoimmune reactions.
- Infectious factors: Previous infections, such as urogenital or intestinal, may serve as triggers for nr-axSpA-associated inflammatory processes.
- Lifestyle: Smoking, stress and a sedentary lifestyle can also contribute to the progression of the disease.
Each of these factors may intersect and exacerbate the effects of the others, creating a multilayered predisposition to the disease. Such interactions highlight the need for a comprehensive approach to the prevention and treatment of nr-axSpA.
Diagnosis of this disease
Diagnosis of non-radiographic axial spondyloarthritis involves evaluation of clinical symptoms, laboratory tests, radiological examinations, and other diagnostic methods. The main symptoms that clinicians pay attention to include:
- Chronic lower back pain that does not respond to conventional analgesics;
- Morning back stiffness lasting more than 30 minutes;
- Pain radiating to the buttocks or thighs.
Laboratory tests are usually aimed at detecting inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Due to the increased inflammatory activity, these parameters can serve as indicators for physicians. In addition, radiological examinations such as magnetic resonance imaging (MRI) can detect signs of inflammation in the sacroiliac joints early in the disease, which is important for early diagnosis. Differential diagnosis is important to exclude other diseases such as osteochondrosis, ankylosing spondylitis, and reactive arthritis, which requires careful and comprehensive assessment of the patient's data.
Treatment
Treatment of non-radiographic axial spondyloarthritis should be individualized and take into account the symptoms, severity of the disease, and the general condition of the patient. General treatment includes:
- Educating patients about the nature of the disease and self-care methods;
- Physical rehabilitation and supportive therapy to restore mobility;
- Using cold and heat therapy to relieve pain.
Pharmacological treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), which are the main method of pain and inflammation control. In case of NSAIDs ineffectiveness, glucocorticosteroids or biological drugs such as TNF-α inhibitors, which show high efficiency in controlling chronic inflammation, can be prescribed. Surgical treatment, although rarely used, may be required in case of severe spinal deformities or significant functional limitations. Other methods such as physiotherapy, osteopathy, acupuncture can be used to improve the general well-being of the patient.
List of medications used to treat this disease
- NSAIDs: ibuprofen, diclofenac, indomethacin;
- Glucocorticosteroids: prednisolone, methylprednisolone;
- Biological drugs: adalimumab, etanercept, infliximab;
- Muscle relaxants: tizanidine, baclofen;
- Physical rehabilitation methods: massage, physiotherapy.
These drugs are used depending on the clinical situation and individual characteristics of the patient in order to achieve maximum relief of the condition and improve the quality of life.
Disease monitoring
Monitoring of non-radiographic axial spondyloarthritis is an important part of disease management, allowing timely adjustments to treatment and prevention of potential complications. Control stages include regular clinical examinations, assessment of pain levels, functional capabilities, and inflammatory biomarkers in the blood. The prognosis of the disease varies; many patients can achieve significant improvements with the right approach to treatment and regular monitoring. Complications may include the development of osteoporosis, spinal deformities, and systemic manifestations such as inflammatory bowel disease, which emphasizes the need for regular screening and monitoring of patients.
Age-related features of the disease
Age-related features of non-radiographic axial spondyloarthritis require special attention. In young patients, the disease may manifest itself more aggressively, often with severe pain and early onset of limitations in movement. In older patients, clinical manifestations may be less pronounced, but systemic changes such as osteoporosis are often observed. It is also important to note that older people may develop comorbidities that complicate the diagnosis and treatment of nr-axSpA. These differences should be taken into account when choosing a treatment strategy and approach to monitoring patients depending on the age category.
Questions and Answers
- What are the main symptoms of non-radiographic axial spondyloarthritis? The main symptoms include chronic lower back pain, morning stiffness and pain radiating to the buttocks.
- How is nr-axSpA diagnosed? Diagnosis is based on clinical evaluation, laboratory tests and radiological examinations such as MRI.
- What medications can be used to treat this disease? Treatment may include NSAIDs, glucocorticosteroids, and biologic therapy.
- What are the risk factors for developing nr-axSpA? Major risk factors include genetic predisposition, physical and chemical exposures, and infectious factors.
- What is the chance of successful treatment for nr-axSpA? With the right approach to treatment, many patients achieve significant relief of symptoms and improved quality of life.
